Laddar...
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first t...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Blackwell Publishing Ltd
2012
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3267050/ https://ncbi.nlm.nih.gov/pubmed/21991938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-0609.2011.01721.x |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|